Since spring 2018, setup of high throughput genotyping analysis, based on Thermofisher microarrays: APMRA (Axiom Precision Medecine Research Arrays). http://thermofisher.com/pmra
Since summer 2017, setup of Nanostring 3D biology technics to measure DNA, RNA and proteins on Fresh Frozen material and Formalin Fixed Paraffin Embedded samples (FFPE).
Since March 2017, the Genomic Platform acquired a Fragment Analyzer, which is a High throughput capillary electrophoresis device (48 well capillary).
What does this device do? This technology allows diverse analyses that quantify and qualify, with high precision, nucleic acids. DNA/RNA molecules from frozen tissues, formalin fixed and paraffin-embedded tissues, CSF, plasma, laser microdissection preparation, ctDNA, as well as products for NGS libraries can be monitored with a large spectrum of concentrations (5 μg /μL to 500 ng/ μL depending on kits).
This equipment was financed, thanks to the support of the Canceropole Ile de France and the Institut Curie.
If you have any questions, do not hesitate to contact us at the platform or to visit this site:
13th of October 13, 2016, the partnership Cambridge Epigenetix (CEGX) and the Institut Curie was renewed for one year.
This partnership led to the creation of an “Epigenome Center” for which the Genomics and NGS platforms have been trained in the processes developed by CEGX. Analysis of DNA methylation (5mC, 5hmC) is currently proposed to the scientific fellowship.
1st of October, 2016, the Genomics Platform and Nanostring signed an agreement for the creation of a backup laboratory in Europe that can performed the Prosigna Breast Cancer Pronostic Gene Signature assay (Pam50 tests).
This agreement is based on the regular activity of the PAM50 tests carried out at the Institut Curie. It allows the update of Nanostring equipments, and doubles the Prosigna test capacities made by the Institut Curie. This accession strengthens the links between Institut Curie and Nanostring.